Deoxyglucose

Deoxyglucose

SCHEMBL4480352

O=CC[C@@H](O)[C@@H](O)[C@@H](O)CO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
PDE4A P27815 1/20 0.41
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
AKR1B1 P15121 1/20 0.38
KDM4E B2RXH2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyglucose SCHEMBL29105105 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL307650 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL148114 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL2315642 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL3019708 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL2065929 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL120125 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL10386937 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL200714 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2
Deoxyglucose SCHEMBL635056 1.00 LMNA (0.50) LMNAL3MBTL1TDP1PDE4AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019150578-A1 METHOD FOR PREPARING CYCLOPENTENONE 株式会社コンポン研究所 2019-08-08 WO disclosed
US-7511160-B2 Lactone derivative and its manufacturing method TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2009-03-31 US disclosed
US-20060058536-A1 Lactone derivative and its manufacturing method TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2006-03-16 US disclosed
EP-0390783-A1 METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-10-10 EP disclosed
US-4937077-A Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose EASTMAN KODAK COMPANY (US) 1990-06-26 US disclosed
WO-1989002224-A1 METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE EASTMAN KODAK COMPANY (US) 1989-03-23 WO disclosed
CN-85107911-A The production method of ellipticine derivative 1987-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058536-A1 Lactone derivative and its manufacturing method CYP51A1, LSS, MRPL21 LMNA 1688/4885L3MBTL1 1173/4885TDP1 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.